Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes

Significant cognitive impairment has been found in 20—30% of patients with clinically isolated syndromes suggestive of multiple sclerosis. In this study we aimed to assess the prognostic value of the presence of cognitive impairment for the conversion to multiple sclerosis in patients with clinically isolated syndromes. All patients with clinically isolated syndromes consecutively referred to our centre since 2002 and who had been followed-up for at least one year underwent cognitive assessment through the Rao’s Battery and the Stroop test. Possible predictors of conversion to clinically definite multiple sclerosis were evaluated through the Kaplan Meier curves and Cox regression analysis. A total of 56 patients (41 women; age 33.2 ± 8.5 years; expanded disability scale score 1.2 ± 0.7) were recruited. At baseline, 32 patients (57%) fulfilled McDonald’s criteria for dissemination in space. During the follow-up (3.5 ± 2.3 years), 26 patients (46%) converted to a diagnosis of multiple sclerosis. In particular, 64% of patients failing ≥ 2 tests and 88% of patients failing ≥ 3 tests converted to multiple sclerosis. In the Cox regression model, the failure of at least three tests (HR 3.3; 95% CI 1.4—8.1; p = 0.003) and the presence of McDonald’s dissemination in space at baseline (HR 3.8; 95% CI 1.5—9.7; p = 0.005), were found to be predictors for conversion to multiple sclerosis. We conclude that cognitive impairment is detectable in a sizable proportion of patients with clinically isolated syndromes. In these subjects cognitive impairment has a prognostic value in predicting conversion to multiple sclerosis and may therefore play a role in therapeutic decision making.

[1]  P. Coyle Early treatment of multiple sclerosis to prevent neurologic damage , 2008, Neurology.

[2]  M. Filippi,et al.  Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives , 2008, Multiple sclerosis.

[3]  G. Koutsis,et al.  Cognitive impairment in different MS subtypes and clinically isolated syndromes , 2008, Journal of the Neurological Sciences.

[4]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[5]  Marco Battaglini,et al.  Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. , 2007, Archives of neurology.

[6]  R. Sperling,et al.  Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis , 2007, Multiple sclerosis.

[7]  H. Hahn,et al.  Brain atrophy and cognitive impairment in multiple sclerosis: a review , 2007, Journal of Neurology.

[8]  J. Pelletier,et al.  Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis , 2007, Multiple sclerosis.

[9]  S. Sorbi,et al.  The Rao’s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population , 2006, Multiple sclerosis.

[10]  J. De Keyser,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[11]  H P Hartung,et al.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes , 2006, Neurology.

[12]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[13]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[14]  N. De Stefano,et al.  Neocortical volume decrease in relapsing–remitting MS patients with mild cognitive impairment , 2004, Neurology.

[15]  P. M. Matthews,et al.  Evidence of early cortical atrophy in MS , 2003, Neurology.

[16]  A Achiron,et al.  Cognitive impairment in probable multiple sclerosis , 2003, Journal of neurology, neurosurgery, and psychiatry.

[17]  J Sastre-Garriga,et al.  New diagnostic criteria for multiple sclerosis , 2003, Neurology.

[18]  David H. Miller,et al.  A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. , 2002, The New England journal of medicine.

[19]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[20]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[21]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[22]  A J Thompson,et al.  Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome , 1999, Multiple sclerosis.

[23]  E. Capitani,et al.  A normative study on visual reaction times and two Stroop colour-word tests , 1998, The Italian Journal of Neurological Sciences.

[24]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[25]  L. Amaducci,et al.  Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. , 1995, Archives of neurology.

[26]  D. Miller,et al.  The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. , 1993, Brain : a journal of neurology.

[27]  M. Ron,et al.  Acute optic neuritis : a cognitive and magnetic resonance imaging study , 1992 .

[28]  S. Rao,et al.  Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.

[29]  Stephen M. Rao,et al.  Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.

[30]  N. Larocca,et al.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.

[31]  E. Warrington,et al.  Cognitive impairment in patients with clinically isolated lesions of the type seen in multiple sclerosis. A psychometric and MRI study. , 1989, Brain : a journal of neurology.

[32]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.